Lundbeck starts phase 1 trial of Lu AA34893 for anxiety disorders

By Elaine Rigoli

Tampa, Fla., March 27 - Lundbeck has started phase 1 clinical trials with its pharmaceutical candidate Lu AA34893 to investigate the tolerability and pharmacokinetic profile of the compound in humans.

Lu AA34893 was selected as a development candidate based on its convincing effect in preclinical animal models suggesting a potential to improve the treatment of depression and anxiety disorders, according to a company news release.

For a number of years, Lundbeck used Cipralex in its research in animals as well as in humans.

"It is important for Lundbeck's research to discover new compounds that may improve the treatment and satisfy the unmet medical needs that currently exist in the treatment of depression and anxiety disorders. Lu AA34893 is a new generation of antidepressants for which preclinical research has demonstrated a superior antidepressant effect compared to Cipralex," Lundbeck's head of research, Peter Høngaard Andersen, said in the release.

Based in Copenhagen, Denmark, Lundbeck is a research-based company in the areas of depression, schizophrenia, Alzheimer's disease and Parkinson's disease.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.